Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Frespaciguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 18
States / cities: San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more

Conditions: Dysphagia
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Stable Chronic Heart Failure
Interventions: CD-NP, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, ORMD-0801 QD, ORMD-0801 BD; Other · Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tustin, California

Conditions: Cannabis Intoxication, Alcohol Intoxication
Interventions: Cannabis, Alcohol, Placebo Cannabis, Placebo Alcohol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertriglyceridemia
Interventions: POM3, Placebo; Drug
Lead sponsor: Provident Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Phenylketonuria
Interventions: PTC923, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more

Conditions: Anemia, Sickle Cell
Interventions: alpha-lipoic acid and acetyl-L-carnitine, Control; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diabetic Macular Edema
Interventions: Tonabersat, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Huntington Beach, California • Loma Linda, California • Oakland, California + 23 more

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Atopic Dermatitis
Interventions: 5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more

Conditions: Anxiety Disorders
Interventions: Duloxetine Hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 19
States / cities: Sherman Oaks, California • Fort Myers, Florida • Atlanta, Georgia + 16 more

Conditions: Rheumatoid Arthritis
Interventions: P38 Inhibitor (4), Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Interventions: amantadine HCl ER, Placebo; Drug
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more

Conditions: Obesity
Interventions: Sibutramine hydrochloride, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 55 Years and older
Enrollment: 10,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Acne Vulgaris
Interventions: B244, Placebo; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Culver City, California

Conditions: Major Depressive Disorder
Interventions: Neuronavigated rTMS, Sham rTMS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hepatitis B
Interventions: Alendronate, Hepatitis B Vaccine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nervous System Disorders
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more

Conditions: Plaque Psoriasis
Interventions: AGN-242428, Placebo; Drug
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more

Conditions: Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cancer, Pain
Interventions: Modafinil; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Actinic Keratosis
Interventions: GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more

Conditions: Psoriasis
Interventions: Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more

Search by objective public record fields.

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

Yale Swallow Protocol in Extubated Patients

CD-NP in Subjects With Stable Chronic Heart Failure

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment

Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

A Study of PTC923 in Participants With Phenylketonuria

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

Evaluation of Tonabersat for DME

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

Dysport® Adult Upper Limb Spasticity

AGN-242428 in the Treatment of Plaque Psoriasis

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

Modafinil in Opioid Induced Sedation

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

Study of Secukinumab With 2 mL Pre-filled Syringes